Drug Profile
Research programme: intranasal HIV vaccine - BlueWillow Biologics
Alternative Names: nanoemulsion-based HIV vaccine - BlueWillow BiologicsLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator NanoBio Corporation
- Developer BlueWillow Biologics; Duke Human Vaccine Institute; National Institutes of Health (USA)
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for HIV infections (Prevention) in USA (Intranasal) (BlueWillow Biologics website, March 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in HIV-infections(Prevention) in USA (Intranasal)
- 07 May 2018 NanoBio Corporation is now called BlueWillow Biologics